Nothing Special   »   [go: up one dir, main page]

NO2020039I1 - Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid - Google Patents

Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid

Info

Publication number
NO2020039I1
NO2020039I1 NO2020039C NO2020039C NO2020039I1 NO 2020039 I1 NO2020039 I1 NO 2020039I1 NO 2020039 C NO2020039 C NO 2020039C NO 2020039 C NO2020039 C NO 2020039C NO 2020039 I1 NO2020039 I1 NO 2020039I1
Authority
NO
Norway
Prior art keywords
ozanimod
pharmaceutically acceptable
acceptable salt
hydrochloride
ozanimod hydrochloride
Prior art date
Application number
NO2020039C
Other languages
English (en)
Original Assignee
Receptos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43992106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2020039(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Receptos Llc filed Critical Receptos Llc
Publication of NO2020039I1 publication Critical patent/NO2020039I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Agronomy & Crop Science (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO2020039C 2009-11-13 2020-11-18 Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid NO2020039I1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US26247409P 2009-11-18 2009-11-18
PCT/US2010/056760 WO2011060392A1 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Publications (1)

Publication Number Publication Date
NO2020039I1 true NO2020039I1 (no) 2020-11-18

Family

ID=43992106

Family Applications (2)

Application Number Title Priority Date Filing Date
NO10830880A NO2498610T3 (no) 2009-11-13 2010-11-15
NO2020039C NO2020039I1 (no) 2009-11-13 2020-11-18 Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO10830880A NO2498610T3 (no) 2009-11-13 2010-11-15

Country Status (32)

Country Link
US (4) US8362048B2 (no)
EP (3) EP3406142B8 (no)
JP (3) JP5650233B2 (no)
KR (2) KR101752124B1 (no)
CN (2) CN105061350B (no)
AU (1) AU2010319983B2 (no)
BR (2) BR122018077504B8 (no)
CA (2) CA2986521C (no)
CY (3) CY1120338T1 (no)
DK (2) DK2498610T4 (no)
EA (2) EA035768B1 (no)
ES (2) ES2858337T3 (no)
FI (1) FI2498610T4 (no)
FR (1) FR20C1059I2 (no)
HK (2) HK1175948A1 (no)
HR (2) HRP20180874T4 (no)
HU (3) HUE054000T2 (no)
IL (2) IL219691B (no)
LT (3) LT3406142T (no)
LU (1) LUC00184I2 (no)
MX (1) MX2012005560A (no)
MY (2) MY161854A (no)
NO (2) NO2498610T3 (no)
NZ (1) NZ599915A (no)
PH (1) PH12015502708A1 (no)
PL (2) PL3406142T3 (no)
PT (2) PT3406142T (no)
RS (2) RS57253B2 (no)
SG (1) SG10201407357PA (no)
SI (2) SI3406142T1 (no)
TR (1) TR201807912T4 (no)
WO (1) WO2011060392A1 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005562A (es) * 2009-11-13 2012-10-05 Receptos Inc Moduladores del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
EA035768B1 (ru) 2009-11-13 2020-08-07 Селджин Интернэшнел Ii Сарл Способ получения соединения, содержащего индановую группу с хиральным атомом углерода в пятичленном кольце индановой группы
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
WO2013191144A1 (ja) * 2012-06-21 2013-12-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規インダンスルファミド誘導体
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
EP3280703A1 (en) 2015-04-06 2018-02-14 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
CN114957157A (zh) 2016-06-14 2022-08-30 瑞塞普托斯有限责任公司 奥扎莫德盐酸盐的晶型及其制备方法
KR102481328B1 (ko) 2016-07-22 2022-12-26 메드샤인 디스커버리 아이엔씨. S1p1 작용제 및 이의 응용
CN109563059A (zh) * 2016-08-19 2019-04-02 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
EP3508481A1 (en) * 2016-09-14 2019-07-10 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of ozanimod hydrochloride, and preparation method therefor
WO2018049632A1 (zh) * 2016-09-14 2018-03-22 杭州领业医药科技有限公司 奥扎莫德的晶型、其制备方法及药物组合物
WO2018064356A1 (en) 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
WO2018157813A1 (zh) * 2017-02-28 2018-09-07 南京明德新药研发股份有限公司 螺环类化合物及其应用
CN110612292A (zh) * 2017-04-07 2019-12-24 杭州领业医药科技有限公司 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
WO2018208855A1 (en) * 2017-05-08 2018-11-15 Celgene International Ii Sarl Sphingosine 1 phosphate receptor agonists for neuroprotection
ES2960051T3 (es) * 2017-05-22 2024-02-29 Egyt Gyogyszervegyeszeti Gyar Proceso para la producción de ozanimod
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CA3061201A1 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
CN110944982A (zh) * 2017-08-31 2020-03-31 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
JP2021511375A (ja) * 2018-01-18 2021-05-06 シージャーヂュアン・サガシティー・ニュー・ドラッグ・デヴェロップメント・カンパニー・リミテッド 三環式化合物の結晶形、塩形及びその製造方法
CN111801096B (zh) 2018-03-20 2024-03-05 卫材R&D管理有限公司 癫痫治疗剂
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
EP3810285A4 (en) 2018-06-25 2022-03-09 Enzo Biochem, Inc. COMPOUNDS MODULATING THE SPHINGOSINE PATHWAY FOR THE TREATMENT OF CANCER
AU2019338657A1 (en) 2018-09-12 2021-03-18 Pharmazell Gmbh A process for the preparation of Ozanimod and its intermediate (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile
AR116479A1 (es) * 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
MX2021006692A (es) 2018-12-07 2021-07-07 Synthon Bv Proceso mejorado para preparar ozanimod.
EP3947362A4 (en) * 2019-03-29 2023-01-04 Receptos Llc SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS
CN113939507A (zh) * 2019-03-29 2022-01-14 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
WO2020205478A1 (en) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulators
EP3959204A4 (en) * 2019-04-26 2022-12-28 Receptos Llc SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
MX2022000651A (es) 2019-07-16 2022-03-11 Synthon Bv Proceso mejorado para preparar ozanimod.
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US20230338336A1 (en) * 2020-01-06 2023-10-26 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN115279740A (zh) * 2020-03-04 2022-11-01 南昌弘益药业有限公司 苯并2-氮杂螺[4.4]壬烷类化合物及其应用
CN115210223A (zh) * 2020-03-04 2022-10-18 南昌弘益药业有限公司 三环类化合物及其应用
IL296536A (en) 2020-03-17 2022-11-01 Enzo Biochem Inc Compounds that modulate the sphingosine pathway for the treatment of coronavirus infection
US20230183194A1 (en) 2020-04-02 2023-06-15 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
WO2022213935A1 (zh) * 2021-04-09 2022-10-13 南昌弘益药业有限公司 噁二唑取代的螺环类化合物及其应用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) * 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
EP0583346A1 (en) 1991-04-12 1994-02-23 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
AU741924B2 (en) * 1998-01-23 2001-12-13 Sankyo Company Limited Spiropiperidine derivatives
AR035585A1 (es) † 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
EP1581509B1 (en) 2002-12-20 2011-01-19 Merck Sharp & Dohme Corp. 1-(amino)indanes as edg receptor agonists
PL3889142T3 (pl) 2003-04-11 2022-09-26 Ptc Therapeutics, Inc. Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji nonsensu i do leczenia choroby
EP1670463A2 (en) * 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
JP4773972B2 (ja) 2003-12-17 2011-09-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
WO2006120577A1 (en) 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
AU2006278718B2 (en) † 2005-08-03 2010-10-07 Secura Bio Inc. Use of HDAC inhibitors for the treatment of myeloma
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
JP5514443B2 (ja) 2005-12-21 2014-06-04 ジョセフ ガブリエル， カテコールアミン調節性タンパク質
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CA2662673A1 (en) * 2006-09-21 2008-03-27 Martin Bolli Phenyl derivatives and their use as immunomodulators
WO2008064320A2 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
JP2010513283A (ja) * 2006-12-15 2010-04-30 アボット・ラボラトリーズ 新規なオキサジアゾール化合物
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008143730A2 (en) 2007-02-28 2008-11-27 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009131090A1 (ja) 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
NZ589617A (en) 2008-05-14 2012-06-29 Scripps Research Inst 3-(Inden-4-yl)-5-(phenyl)-1,2,4-oxadiazole and 3-(tetralin-5-yl)-5-(phenyl)-1,2,4-oxadiazole derivatives
CN102066752B (zh) * 2008-06-13 2014-02-19 (学)斗源学院 具有回转阀的往复式压缩机
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
EA035768B1 (ru) 2009-11-13 2020-08-07 Селджин Интернэшнел Ii Сарл Способ получения соединения, содержащего индановую группу с хиральным атомом углерода в пятичленном кольце индановой группы
MX2012005562A (es) 2009-11-13 2012-10-05 Receptos Inc Moduladores del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
CN105130922A (zh) 2009-11-13 2015-12-09 瑞塞普托斯公司 选择性的杂环1-磷酸鞘氨醇受体调节剂
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD

Also Published As

Publication number Publication date
IL267956A (en) 2019-09-26
CA2986521A1 (en) 2011-05-19
FR20C1059I1 (no) 2020-12-25
DK2498610T4 (da) 2024-09-09
KR101721716B1 (ko) 2017-04-10
JP5982705B2 (ja) 2016-08-31
RS57253B2 (sr) 2024-10-31
SG10201407357PA (en) 2014-12-30
KR20120102704A (ko) 2012-09-18
LTPA2020533I1 (lt) 2020-12-10
EP2498610B2 (en) 2024-06-19
IL219691A0 (en) 2012-07-31
US10239846B2 (en) 2019-03-26
CY1120338T1 (el) 2019-07-10
MY161854A (en) 2017-05-15
BR112012011427A2 (pt) 2015-10-06
EP2498610A4 (en) 2013-05-22
ES2858337T3 (es) 2021-09-30
CN102762100A (zh) 2012-10-31
RS57253B1 (sr) 2018-08-31
US20130231326A1 (en) 2013-09-05
MY189750A (en) 2022-03-02
LTC2498610I2 (lt) 2022-06-10
CY1124121T1 (el) 2022-05-27
PH12015502708B1 (en) 2016-10-17
CN105061350A (zh) 2015-11-18
IL219691B (en) 2019-07-31
HUS2000045I1 (hu) 2020-12-28
FR20C1059I2 (fr) 2021-12-10
JP2015038145A (ja) 2015-02-26
US20170320839A1 (en) 2017-11-09
KR101752124B1 (ko) 2017-06-28
JP5650233B2 (ja) 2015-01-07
EP3406142B8 (en) 2021-03-03
PL2498610T3 (pl) 2018-08-31
LT3406142T (lt) 2021-06-10
HK1213874A1 (zh) 2016-07-15
NZ599915A (en) 2014-07-25
ES2673160T3 (es) 2018-06-20
AU2010319983A2 (en) 2013-09-12
PT3406142T (pt) 2021-03-26
CA2780772A1 (en) 2011-05-19
PH12015502708A1 (en) 2016-10-17
EA201690391A1 (ru) 2016-08-31
SI2498610T1 (en) 2018-07-31
MX2012005560A (es) 2012-10-05
TR201807912T4 (tr) 2018-06-21
RS61829B1 (sr) 2021-06-30
NO2498610T3 (no) 2018-08-11
HUE037535T2 (hu) 2018-09-28
CA2986521C (en) 2020-06-30
SI3406142T1 (sl) 2021-08-31
US20110172202A1 (en) 2011-07-14
BR112012011427B1 (pt) 2021-04-20
US20150299149A1 (en) 2015-10-22
JP2014122208A (ja) 2014-07-03
CY2020035I2 (el) 2021-03-12
PT2498610T (pt) 2018-06-19
EA035768B1 (ru) 2020-08-07
CN102762100B (zh) 2015-07-01
HRP20210446T1 (hr) 2021-05-14
LT2498610T (lt) 2018-06-11
EA024801B1 (ru) 2016-10-31
SI2498610T2 (sl) 2024-10-30
PL3406142T3 (pl) 2021-08-30
BR112012011427B8 (pt) 2021-05-25
EP2498610B1 (en) 2018-03-14
KR20160149317A (ko) 2016-12-27
HK1175948A1 (en) 2013-07-19
LUC00184I2 (no) 2024-07-01
HUE054000T2 (hu) 2021-08-30
DK3406142T3 (da) 2021-03-22
CN105061350B (zh) 2018-05-29
AU2010319983B2 (en) 2015-03-12
EP3868377A1 (en) 2021-08-25
IL267956B (en) 2021-01-31
DK2498610T3 (en) 2018-06-14
HRP20180874T4 (hr) 2024-09-27
WO2011060392A1 (en) 2011-05-19
EA201290323A1 (ru) 2013-05-30
US8362048B2 (en) 2013-01-29
FI2498610T4 (fi) 2024-08-29
EP3406142A1 (en) 2018-11-28
BR122018077504B8 (pt) 2021-05-25
EP2498610A1 (en) 2012-09-19
BR122018077504B1 (pt) 2021-05-11
HRP20180874T1 (hr) 2018-07-13
US9388147B2 (en) 2016-07-12
EP3406142B1 (en) 2020-12-23
CY2020035I1 (el) 2021-03-12
AU2010319983A1 (en) 2012-05-31
JP2013510885A (ja) 2013-03-28
CA2780772C (en) 2018-01-16

Similar Documents

Publication Publication Date Title
NO2020039I1 (no) Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
NO2020034I1 (no) Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
NO2023017I1 (no) Mitapivat or a pharmaceutically acceptable salt thereof, in particular mitapivat sulfate
NO2020037I1 (no) alpelisib eller et farmasøytisk akseptabelt salt derav
NO2019024I1 (no) Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2022033I1 (no) Rimegepant or a pharmaceutically acceptable salt thereof
NO2020006I1 (no) upadacitinib or a pharmaceutically acceptable salt thereof
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NO2023023I1 (no) Maralixibat, or a pharmaceutically acceptable salt thereof, in particular maralixibat chloride
NO2017059I1 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav
NO2023047I1 (no) Cedazuridine, or a pharmaceutically acceptable salt thereof
FIC20240031I1 (fi) Sparsentaani tai sen farmaseuttisesti hyväksyttävä suola
NO2022044I1 (no) daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
FIC20240026I1 (fi) Etrasimodi tai sen farmaseuttisesti hyväksyttävä suola, kuten etrasimodiarginiini
NO2019012I1 (no) Enkorafenib eller et farmasøytisk akseptabelt salt eller solvat derav
NO2020018I1 (no) Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NO2019042I1 (no) Talazoparib, eventuelt i form av et farmasøytisk aksepterbart salt
NO2015012I2 (no) Ombitasvir, eller et farmasøytisk akseptabelt salt derav
FIC20240016I1 (fi) Dolutegraviiri tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien dolutegraviirinatrium, ja lamivudiini
NO2024006I1 (no) Piflufolastat (18F) or a pharmaceutically acceptable salt thereof
NO2021033I1 (no) Selineksor eller et farmasøytisk akseptabelt salt derav
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
NO2016016I1 (no) Lesinurad, eller et farmasøytisk akseptabelt salt derav
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
FIC20200022I1 (fi) Yhdistelmä, joka käsittää fosnetupitanttia tai sen farmaseuttisesti hyväksyttävää suolaa ja palonosetronia tai sen farmaseuttisesti hyväksyttävää suolaa